List of Xaciato drug patents
Xaciato is owned by Dare.
Xaciato contains Clindamycin Phosphate.
Xaciato has a total of 1 drug patent out of which 0 drug patents have expired.
Xaciato was authorised for market use on 07 December, 2021.
Xaciato is available in gel;vaginal dosage forms.
Xaciato can be used as method of treating bacterial vaginosis by single dose administration of a clindamycin pharmaceutical gel formulation.
The generics of Xaciato are possible to be released after 22 September, 2036.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11129896 | DARE | Topical formulations and treatments |
Sep, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Dec 7, 2024 |
| Generating Antibiotic Incentives Now (GAIN) | Dec 7, 2029 |
Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 07 December, 2021
Treatment: Method of treating bacterial vaginosis by single dose administration of a clindamycin pharmaceutical gel formulation
Dosage: GEL;VAGINAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic